Bruce Booth - Mar 11, 2024 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Director
Signature
/s/ Ommer Chohan, Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Mar 11, 2024
Transactions value $
-$14,912,376
Form type
4
Date filed
3/13/2024, 07:52 PM
Previous filing
Mar 5, 2024
Next filing
Mar 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Sale -$1.59M -37.2K -0.75% $42.77 4.93M Mar 11, 2024 See footnote F1, F2, F3
transaction KYMR Common Stock Sale -$222K -5.12K -0.1% $43.42 4.93M Mar 11, 2024 See footnote F1, F3, F4
transaction KYMR Common Stock Sale -$335K -7.84K -0.88% $42.77 882K Mar 11, 2024 See footnote F2, F5, F6
transaction KYMR Common Stock Sale -$45.4K -1.05K -0.12% $43.42 881K Mar 11, 2024 See footnote F4, F5, F6
transaction KYMR Common Stock Sale -$5.29M -126K -2.56% $41.94 4.8M Mar 12, 2024 See footnote F1, F3, F7
transaction KYMR Common Stock Sale -$365K -8.58K -0.18% $42.52 4.79M Mar 12, 2024 See footnote F1, F3, F8
transaction KYMR Common Stock Sale -$1.11M -26.5K -3% $41.94 855K Mar 12, 2024 See footnote F5, F6, F7
transaction KYMR Common Stock Sale -$77.3K -1.82K -0.21% $42.52 853K Mar 12, 2024 See footnote F5, F6, F8
transaction KYMR Common Stock Sale -$4.57M -108K -2.26% $42.19 4.68M Mar 13, 2024 See footnote F1, F3, F9
transaction KYMR Common Stock Sale -$286K -6.69K -0.14% $42.84 4.68M Mar 13, 2024 See footnote F1, F3, F10
transaction KYMR Common Stock Sale -$961K -22.8K -2.67% $42.19 830K Mar 13, 2024 See footnote F5, F6, F9
transaction KYMR Common Stock Sale -$59.4K -1.39K -0.17% $42.84 829K Mar 13, 2024 See footnote F5, F6, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10).
F3 These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive.
F5 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.
F6 The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive.